Orange County Urology Associates, Inc | Orange County Urology Associates, Inc

Dr. Meaglia earns Center of Excellence designation for Rezūm

Dr. James Meaglia, Orange County Urology Associates Designated as a Center of Excellence for Rezūm™ water Vapor Therapy, a Treatment for Benign Prostatic Hyperplasia (BPH), or Enlarged Prostate

Center of Excellence Recognizes High Degree of Experience with New Technology

MARLBOROUGH, Mass. (July 22, 2020) – Boston Scientific Corporation (NYSE: BSX) today announced that Dr. James Meaglia and Orange County Urology Associates (OCUA) have been designated as a Center of Excellence for Rezūm™ Water Vapor Therapy treatment – a minimally invasive in-office procedure for men looking to treat their benign prostatic hyperplasia (BPH), not just the symptoms. Boston Scientific owns the Rezūm® system technology, a minimally invasive therapy (MIT) for patients with symptomatic benign prostatic hyperplasia (BPH) or enlarged prostate.

Dr. Meaglia has performed more than 200 Rezūm implant procedures.

Rezūm Therapy uses natural water vapor to reduce the size of the prostate and provide lasting symptom relief from BPH without invasive surgery or some of the potential side effects of prescription drugs¹.

Dr James Meaglia
James Meaglia, M.D
Boston
Rezum

The Center of Excellence designation recognizes Dr. Meaglia’s high degree of experience with Rezūm Water Vapor Therapy and commitment to delivering significant, lasting symptom relief to men suffering from benign prostatic hyperplasia (BPH). BPH is a condition in which a man’s prostate enlarges and squeezes the urethra, causing frustrating symptoms such as frequent or urgent urination, a weak or interrupted urine stream, and the need to get up several times a night to urinate. It affects about 50% of men by age 60, and up to 90% of men by age 85².

“Being designated as the first Rezūm Center of Excellence in Orange County, CA, is a meaningful recognition for us as we strive to provide the best possible minimally invasive treatments of urological conditions for patients in our region,” said Dr. Meaglia. “For years, the primary options for treating BPH were through behavior modifications, medications or invasive surgery. However, medications may not work for everyone and may have undesirable side effects such as dizziness, sexual dysfunction and lower sex drive³ With Rezūm Therapy, we’re able to provide relief of BPH for men who do not want to take medication or want to avoid invasive surgery and implants.”

Powered by convective water vapor energy, the Rezūm System delivers targeted, controlled doses of the stored thermal energy in water vapor directly to the region of the prostate gland with the obstructive tissue causing the lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). During Rezūm Therapy, which takes place during one short office visit, natural water vapor is released throughout the targeted prostate tissue. When the steam contacts the tissue and turns back to water, it releases energy, killing the excess prostate cells that squeeze the urethra. Over time, the body’s natural healing response removes the dead cells and shrinks the prostate. With the extra tissue removed, the urethra opens, relieving BPH symptoms while preserving erectile and urinary function¹ The procedure does not require general anesthesia and is performed under oral sedation or local anesthesia¹

Rezūm Therapy has undergone extensive clinical trials to evaluate the safety and efficacy of the treatment¹ It is now included in the American Urological Association’s BPH treatment guidelines and has four-year follow-up data showing its ability to treat prostates with hyperplasia of the central zone, lateral lobe and/or median lobe.4 Rezūm Therapy is currently being used in many leading urology practices throughout the United States. To date, more than 55,000 patients around the world have been successfully treated with Rezūm Therapy.

About Boston Scientific

Boston Scientific is dedicated to transforming lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 35 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com

The Boston Scientific Urology and Pelvic Health business provides a range of treatment options for men’s and women’s urological and gynecological conditions. The Rezūm system complements the company’s existing portfolio of treatment options for symptomatic BPH, which includes the GreenLight XP laser therapy system.

About Orange County Urology Associates

Orange County Urology Associates (OCUA) is a state-of-the-art, large urology practice serving all of Orange County with offices in Laguna Hills, Irvine, Mission Viejo (two convenient locations), San Clemente, Fountain Valley and Newport Beach. OCUA also treats patients from Los Angeles, San Diego, Anaheim, Irvine, Laguna Beach, Lake Forest, Huntington Beach and Long Beach. We also treat patients from around the world. OCUA provides complete male, female and pediatric urology care. Our 11 experienced urologists consistently deliver expert care, utilizing the latest technology and techniques, with advanced diagnostic tests and minimally invasive surgeries.

The urologists at OCUA, along with the 70 physician assistants, nurses and office staff, provide exceptional personalized care. They pay careful attention to the special needs of each individual patient and all family members. They offer diagnosis and solutions for the full spectrum of urologic conditions, including:

Bladder control problems
Overactive bladder
Neurogenic bladder
Pain when urinating
Blood in urine
Urinary tract infection
Prostatitis
Prostate enlargement
Prostate cancer
Premature ejaculation
Impotence
Kidney stones
Kidney cancer
Urology surgical procedures
da Vinci® robotic nephrectomy
da Vinci® robotic prostatectomy
Male reconstructive surgery
Overactive bladder treatments
Male infertility treatment
Urinary incontinence treatment (including female urinary incontinence treatment)
Prostatitis treatment
Prostate cancer treatment
ED treatments
Curved penis treatment
Vasectomy & vasectomy reversal
ESWL
STD treatments
Testicular cancer treatment

Orange County Urology Associates is a member of LUGPA, the Large Urology Group Practice Association, which represents more than 1,800 urologists across the country. LUGPA’s goal is to provide urologic surgeons in large group practices the means to access resources, technology and management tools so they can provide their services in an efficient, cost effective and clinically superior manner.

Discover today’s most advanced, effective urology care. Trust Orange County Urology Associates for real solutions. Call us at 949.855.1101 or visit us on the Web at: www.orangecountyurology.com.

For more information, visit OrangeCountyUrology.com or Rezum.com

McVary KT, Rogers T, Roehrborn CG. Rezūm water vapor thermal therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia: 4-year results from randomized controlled study. Urology. 2019 Apr;126:171-9.
What is BPH? Urology Care Foundation website. https://www.urologyhealth.org/urologic-conditions/benign-prostatic-hyperplasia-(bph)
Accessed July 22,2020.
Roger K and Gilling P. Fast Facts: Benign Prostatic Hyperplasia, 7th edition. Health Press. 2011.
McVary KT, Gange SN, Gittleman MC et al. Minimally invasive prostate convective water vapor energy (WAVE) ablation: A multicenter, randomized, controlled study for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2016 May;195(5):1529-38.
Date on file with Boston Scientific.

* Results from case studies are not necessarily predictive of results in other cases. Results in other cases may vary.

IMPORTANT INFORMATION: These materials are intended to describe common clinical considerations and procedural steps for the use of referenced technologies but may not be appropriate for every patient or case. Decisions surrounding patient care depend on the physician’s professional judgment in consideration of all available information for the individual case.
Boston Scientific (BSC) does not promote or encourage the use of its devices outside their approved labeling. Case studies are not necessarily representative of clinical outcomes in all cases as individual results may vary.

Rezum.com is a website sponsored by Boston Scientific.

Caution: U.S. Federal law restricts this device to sale by or on the order of a physician.

All trademarks are the property of their respective owners.

MEDIA CONTACT:

Shawnie Anderson

Boston Scientific Corporation

917-471-1334

Shawnie.Anderson@bsci.com

Dr. Meaglia earns Center of Excellence designation for UroLift

NeoTract Designates Dr. James Meaglia as UroLift^® Center of Excellence

Designation Recognizes Dr. Meaglia’s Commitment to Exemplary Care, Extensive UroLift^® System Experience

PLEASANTON, Calif. (July 21, 2020 via PRWeb) – NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced that James Meaglia, M.D., Orange County Urology Associates in Mission Viejo, CA, has been designated as a UroLift^® Center of Excellence.

Dr James Meaglia
James Meaglia, M.D

The designation recognizes that Dr. Meaglia has achieved a high level of training and experience with the UroLift^® System and demonstrated a commitment to exemplary care for men suffering from symptoms associated with Benign Prostatic Hyperplasia (BPH), also known as enlarged prostate.Dr. Meaglia has performed more than 200 Rezūm™ implant procedures.

Over 40 million men in the United States are affected by BPH, a condition that occurs when the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. Symptoms of BPH often include interrupted sleep and urinary problems and can cause loss of productivity, depression and decreased quality of life.

“Dr. James Meaglia has earned the UroLift Center of Excellence designation for his dedication to improving the lives of men who previously suffered from BPH symptoms and delivering superior patient outcomes with the UroLift System treatment,” said Dave Amerson, president of the Teleflex Interventional Urology business unit.

The UroLift Center of Excellence program is designed to highlight urologists who are committed to educating their patients on BPH and the UroLift System as a treatment option and consistently seek to deliver excellent patient outcomes and experiences.

Recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines, the FDA-cleared Prostatic Urethral Lift procedure using the UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to BPH. The UroLift permanent implants, delivered during a transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue.

Medication is often the first-line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of medication treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts, heats or removes prostate tissue to open the blocked urethra. While current surgical options can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction, and retrograde ejaculation.

About the UroLift^® System

The FDA-cleared UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function*1,2. Patients also experienced a significant improvement in quality of life. Over 100,000 men have been treated with the UroLift System in the U.S. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The Prostatic Urethral Lift procedure using the UroLift System is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at www.UroLift.com.

About Orange County Urology Associates (OCUA)

Orange County Urology Associates is a state-of-the-art, large urology practice serving all of Orange County with offices in Laguna Hills, Irvine, Mission Viejo (two convenient locations), San Clemente, Fountain Valley and Newport Beach. OCUA also treats patients from Los Angeles, San Diego, Anaheim, Irvine, Laguna Beach, Lake Forest, Huntington Beach and Long Beach. We also treat patients from around the world. OCUA provides complete male, female and pediatric urology care. Our 11 experienced urologists consistently deliver expert care, utilizing the latest technology and techniques, with advanced diagnostic tests and minimally invasive surgeries.

Bladder control problems
Overactive bladder
Neurogenic bladder
Pain when urinating
Blood in urine
Urinary tract infection
Prostatitis
Prostate enlargement
Prostate cancer
Premature ejaculation
Impotence
Kidney stones
Kidney cancer
Urology surgical procedures
da Vinci^® robotic nephrectomy
da Vinci^® robotic prostatectomy
Male reconstructive surgery
Overactive bladder treatments
Male infertility treatment
Urinary incontinence treatment (including female urinary incontinence treatment)
Prostatitis treatment
Prostate cancer treatment
ED treatments
Curved penis treatment
Vasectomy & vasectomy reversal
ESWL
STD treatments
Testicular cancer treatment

Orange County Urology Associates is a member of LUGPA, the Large Urology Group Practice Association, which represents more than 1,800 urologists across the country. LUGPA’s goal is to provide urological surgeons in large group practices the means to access resources, technology and management tools so they can provide their services in an efficient, cost effective and clinically superior manner.

About NeoTract | Teleflex Interventional Urology

A wholly owned subsidiary of Teleflex Incorporated, the Interventional Urology Business Unit is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. Our initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving normal sexual function*1,2. Learn more at www.NeoTract.com.

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit www.teleflex.com.

Teleflex is the home of Arrow^®, Deknatel^®, Hudson RCI^®, LMA^®, Pilling^®, Rusch^®, UroLift^® and Weck^® – trusted brands united by a common sense of purpose.

For Teleflex Incorporated: Jake Elguicze, 610.948.2836 Treasurer and Vice President, Investor Relations

Media:

Nicole Osmer, 650.454.0504

nicole@healthandcommerce.com

*No instances of new, sustained erectile or ejaculatory dysfunction

Roehrborn, J Urology 2013 LIFT Study
McVary, J Sex Med 2016

Dr. Moses Kim Performs First Single Port Robotic Prostatectomy in SoCal

Hoag Performs First Robotic Prostatectomy in Southern California

IRVINE, Calif., February 26, 2020 – Hoag Hospital Irvine today became the first in Southern California to perform a robotic prostatectomy for the treatment of prostate cancer, using the new da Vinci® single port (SP) system, a cutting-edge robotic-assisted technology that few hospitals in the world have yet acquired.

Dr Moses Kim
Moses Kim, M.D., Ph.D.

“We have the privilege of being one of the first hospitals in the nation to obtain this fourth-generation robotic tool that allows us to perform ever more precise surgeries with less stress on the patient’s body,” said Moses Kim, M.D., Ph.D., President of Orange County Urology Associates and Chair of Urology at Hoag, who performed the recent surgery. “This is another example of how Hoag is a leader in the field of robotic surgery.”

“This advanced technology allows our physicians to consistently deliver the safest, highest-quality care to our robotic surgery patients,” said Robert T. Braithwaite, Hoag president and CEO. “While robotics is still just one tool in a surgeon’s tool box, minimally-invasive options are becoming the standard of care for many procedures in a variety of areas of expertise at Hoag, including cancer, women’s and heart programs, as well as general surgery.”

“Single port,” means that only one small incision is needed to insert all the tiny tools necessary to remove part or all of a person’s prostate. Previously, five incisions were needed for laparoscopic prostatectomies.

The new tool ensures faster recovery times and is less disfiguring, Dr. Kim said. The robotic system is approved by the U.S. Food & Drug Administration for use in prostate cancer, kidney cancer and advanced urinary tract reconstruction surgery.

The new tool helps Hoag’s efforts to minimize or reduce any possible side effects of surgery.

“The ability to perform these complex procedures through a one-inch incision will make a tremendous difference to our patients. Already, Hoag is a leader in robotic surgeries and the highest surgical volume center for prostate and bladder surgeries in Orange County,” Dr. Kim said.

Hoag is a Center of Excellence in Robotic Surgery (COERS), as designated by the Surgical Review Corporation. The designation recognizes the elite hospitals and surgeons nationwide who demonstrate an unparalleled commitment and ability to consistently deliver safe, effective, evidence-based care.

Surgeons at Hoag perform the fifth highest volume of total robotic cases annually in the country, which allows the hospital to deliver the safest, highest-quality care. This new tool will enhance that capability and further Hoag’s commitment to patient care.

“Robotic surgery improves outcomes, which is important for patient satisfaction,” Dr. Kim said. “We are not just focused on treating cancer, we are also dedicated to maintaining our patients’ quality of life.”

ABOUT HOAG MEMORIAL HOSPITAL PRESBYTERIAN

Hoag is an approximately $1 billion nonprofit, regional health care delivery network in Orange County, California, that treats more than 30,000 inpatients and 480,000 outpatients annually. Hoag consists of two acute-care hospitals – Hoag Hospital Newport Beach, which opened in 1952, and Hoag Hospital Irvine, which opened in 2010 – in addition to nine health centers and 13 urgent care centers. Hoag is a designated Magnet® hospital by the American Nurses Credentialing Center (ANCC). Hoag offers a comprehensive blend of health care services that includes five institutes providing specialized services in the following areas: cancer, heart and vascular, neurosciences, women’s health, and orthopedics through Hoag’s affiliate, Hoag Orthopedic Institute, which consists of an orthopedic hospital and two ambulatory surgical centers. Hoag has been named one of the Best Regional Hospitals in the 2019 – 2020 U.S. News & World Report. For an unprecedented 23 years, residents of Orange County have chosen Hoag as one of the county’s best hospitals in a local newspaper survey. Visit www.hoag.org for more information.

Dr. Spitz releases The Penis Book with major publisher

Read the book launch press release

Read the book reviews

Read a Q&A with the author

View an image of the book cover

Read the author’s bio

Click here to buy the book

Dr. Spitz makes 50th appearance on The Doctors TV show

Dr. Spitz

Dr. Aaron Spitz

LAGUNA HILLS, Calif. (Oct. 16, 2018) – Dr. Aaron Spitz, a board-certified urologist with Orange County Urology Associates, is a frequent guest on the daytime health and medical TV show, The Doctors. He recently made his 50th appearance on the show to provide context and medical advice on a wide variety of health conditions.

Here are some links to Dr. Spitz’s recent appearances:

Good or bad idea? Cool air-flow underwear for men
www.thedoctorstv.com/videos/cooling-air-flow-underwear-buzz-bust

Explain Peyronie’s disease
www.thedoctorstv.com/videos/what-peyronies-disease

Unusual way to determine your risk of heart disease
www.thedoctorstv.com/articles/how-simple-piece-string-can-tell-you-about-your-risk-heart-disease

Can fruit flies help us better understand sex?
www.thedoctorstv.com/videos/can-fruit-flies-help-us-better-understand-human-sex

Hack or whack?
www.thedoctorstv.com/videos/shine-your-shoes-lemon-juice-and-olive-oil

Shingles: causes and best treatments
www.thedoctorstv.com/videos/shingles-what-are-causes-and-best-treatments

Are you a player?
www.thedoctorstv.com/videos/are-you-involved-several-night-stand-or-friends-benefits-situation

Broken genitalia from self-pleasuring too much
www.thedoctorstv.com/videos/broken-genitalia-from-too-much-self-pleasuring

Cause of messy urination
www.thedoctorstv.com/videos/broken-genitalia-from-too-much-self-pleasuring

Dr. Meaglia now offers revolutionary Rezum® therapy to select BPH patients

Dr. James Meaglia is now offering Orange County Urology patients the Rezum® system, a minimally invasive treatment option for men with benign prostatic hyperplasia (BPH).

DrMeaglia

Designed to be performed in a clinical setting, Rezum is an FDA approved treatment that uses the stored thermal energy in water vapor (steam) to treat the extra prostate tissue that is causing symptoms such as frequency, urgency, irregular flow, weak stream, straining, and getting up at night to urinate.

BPH is a localized enlargement of the prostate gland in aging adult men. Nearly 12 million U.S. men suffer from BPH related symptoms that may require therapy, yet more than half choose not to do anything to address their BPH symptoms. Their reasons include not wanting to start new prescriptions, hesitations around the potential side effects of drugs, and concerns about the potential side effects or complications of current minimally invasive BPH treatments or surgical procedures.

“I am pleased to now offer select patients the Rezum® procedure as a treatment for benign prostatic hyperplasia (BPH). Rezum is administered on an outpatient basis and can be performed under oral sedation or local anesthesia. Research studies have shown that the Rezum treatment allows men to retain sexual function unlike many other existing BPH treatments,” Dr. Meaglia said.

Dr. James Meaglia is the first doctor at Orange County Urology Associates certified to perform the FDA approved Rezum therapy. For years, the primary options for treating BPH were through medications or surgery, making Rezum a new option for patients who are dissatisfied with their current choices for treating BPH.

How Rezum Works

The Rezum therapy is completed in a single visit; there is no need for ongoing therapy.

It works by delivering very small amounts of steam to the enlarged prostate. This process damages the cells causing obstruction, thus reducing the overall size of the prostate and the symptoms associated with BPH such as:

A weak urine stream
Trouble starting the flow of urine
Starting and stopping again when urinating
Not emptying your bladder completely
Urinating more often, especially at night
Sudden urges to urinate
Leaking or dribbling after you urinate
Straining to urinate.

Patient Education Video (English)

Patient Education Video (Spanish)

Next Step: Schedule an Appointment

Patients interested in a consultation with Dr. Meaglia to determine if they are a candidate for the Rezum® system should call appointment scheduling at (949) 855-1101.

Procedure Day

Treatment is a minimally invasive procedure conducted in-office that does not require general anesthesia. Patients need to be driven home after the procedure. Over the next several days, patients can gradually resume their regular activities.

Symptom Improvement

BPH symptoms may improve in as little as two weeks.

Rezum Procedure Quick Facts:

Using water vapor therapy, Rezum is a minimally invasive, single-visit, out-patient procedure shown to significantly reduce the symptoms of BPH.
Delivers small amounts of steam to obstructing prostatic tissue.
Treated tissue is reabsorbed into the body naturally, reducing the overall size of the prostate and the symptoms associated with BPH.
Rezum treatment is appropriate for small to medium prostate lobes, between 30g and 80g.

Benign prostatic hyperplasia (BPH), or an enlarged prostate, is a common condition that can cause bothersome urinary symptoms. As men age, their likelihood of experiencing the bothersome symptoms of BPH increases. Fifty percent of men age 50 and older have BPH, and eighty percent of men age 80 and older have the condition.

Frequently Asked Questions

Does an enlarged prostate improve without treatment?

Early on, enlarged prostate symptoms may come and go, so taking a “wait and see” approach to mild symptoms is reasonable. Over the long-term, however, symptoms tend to get gradually worse.

Is the Rezum therapy covered by insurance?

Rezum therapy is covered by most insurance plans to treat benign prostatic hyperplasia (BPH).

If the Rezum therapy is new, how do I know it is safe?

The Rezum therapy has undergone extensive clinical trials to evaluate the safety and efficacy of the treatment, and was approved by the FDA in late 2015.

Highlights of the therapy include:

Performed in-office and patients can be driven home afterward
Does not require general anesthesia
Relieves symptoms safely and effectively
Is an alternative to BPH daily medications
Provides noticeable symptom improvement within 2 weeks
Preserves erectile and urinary functions
Allows patients to return to regular activities within a few days
Is considered medically necessary by Medicare and is covered by most private insurance plans.

Illustration credit: Rezum® system

Benign prostatic hyperplasia (BPH) is an enlargement of the prostate gland. The condition affects 12 million men in the U.S., with nearly 800,000 newly diagnosed each year. An enlarged prostate squeezes down on the urethra, causing lower urinary tract symptoms. After the Rezum® system therapy has been performed, over time the body’s natural healing response removes the dead cells, shrinking the prostate. With the extra tissue removed, the urethra opens, reducing BPH symptoms. Most patients begin to experience symptom relief in as soon as 2 weeks and maximum benefit will occur in about 3 months.

Dr. Meaglia performs his 150th UroLift® implant

LAGUNA BEACH, Calif. (January 15, 2017) – Dr. James Meaglia of Orange County Urology Associates has performed his 150th UroLift® implant on a patient suffering from benign prostatic hyperplasia (BPH), a condition in which the prostate enlarges as men age.

More than 500 million men worldwide suffer from BPH each year. One in four men experience symptoms of an enlarged prostate by the age of 55, and that rate increases to 90 percent in men over the age of 70. The most common symptom of BPH is difficulty voiding. Chronic lower urinary tract symptoms associated with BPH can cause loss of productivity and sleep, depression, and decreased quality of life.

Past treatments for BPH meant that men had a high risk of urinary incontinence, erectile dysfunction (ED), and retrograde (dry) orgasm. Today, UroLift is a surgical device approved by the FDA in the United States for the treatment of BPH that completely eliminates these potential risks.
Unlike previous BPH treatments, the UroLift system directly opens the urethra without cutting, heating, or removing prostate tissue. It uses tiny metal anchors (like staples) to compress the prostate gland, which opens up the urinary channel that runs through the middle of it.

“This allows urine to flow again normally. Using this new surgical approach, patients experience very rapid and durable relief,” Dr. Meaglia said. “I continue to see excellent clinical outcomes using the UroLift system.”

He added: “This treatment option has been very successful for many of my BPH patients who are unhappy with medication therapy and are concerned about the lengthy recovery and side effects common with other procedures to treat BPH.”
Dr. Meaglia pioneered UroLift in Orange County in November 2014.

He said in certain instances, the procedure can now be done as an in-office procedure. This eliminates the need for anesthesia and a brief hospitalization. An in-office UroLift procedure still takes about 15-20 minutes to complete.
“The risks of the procedure are the same whether it’s done in-office, or in the operating room with anesthesia. There still is no risk of incontinence or impotence,” Dr. Meaglia said.

Patients also experienced a significant improvement in quality of life. The most common adverse events reported include blood in the urine, a burning sensation during urination, urinary urgency, or pelvic pain. Most symptoms were mild to moderate in severity and resolved within two weeks after the procedure.

Medication is often the first line therapy for BPH, but relief can be inadequate and temporary. Side effects can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using their drugs. For these patients, the classic alternative has been surgery that cuts or heats prostate tissue to open the blocked urethra. Although effective, patients often require an overnight stay with a catheter for up to a few days following these procedures. There is often a variable period of irritative voiding symptoms before the symptom relief is fully realized. Even the “gold standard” surgery, TURP (transurethral resection of the prostate), can leave a small percentage of patients with permanent side effects such as urinary incontinence or erectile dysfunction. The TURP does, however, have a high risk of retrograde ejaculation (dry orgasm).

In a two-year randomized controlled study of UroLift in 206 people, which was published in Urology Practice (a journal of the American Urological Association), symptoms, quality of life, and urinary flow improved rapidly and remained durable to two years, with only 7.5% of the men who had the UroLift system needing additional BPH procedures. Treated men returned to normal activity within eight days and showed significant improvement in symptoms by two weeks. While urinary symptoms were effectively treated, not a single patient lost ejaculatory or erectile function as a result of the treatment.

By comparison, 65% of men undergoing the standard surgery (transurethral resection of the prostate, TURP) lose the ability to ejaculate.

Important caveat: The UroLift is not appropriate for all men. Some men may have a prostate that is too large, or not ideally shaped, to allow the procedure to be truly effective. An evaluation will be performed by the urologist prior to recommending the procedure to ensure proper patient selection.

“The advent of the UroLift treatment system underscores the need for men with BPH to discuss male orgasmic dysfunction with their doctor prior to treatment,” Dr. Meaglia said.
The UroLift system is available in the U.S., Europe, Australia, Mexico, South Korea and Canada. Learn more at www.UroLift.com.

Orange County Urology Welcomes Dr. Daniel Su

LAGUNA HILLS, Calif. (July 25, 2016) – Dr. Daniel Su, a urologist and urologic oncology surgeon, has joined Orange County Urology Associates. He started work on July 25, 2016.

Dr. Su comes to OCUA from the National Institutes of Health/National Cancer Institute in Bethesda, MD, where he most recently served as a Senior Surgeon for the Urology Oncology Branch.

Dr. Su attended medical school and performed his internship and residency at Rutgers Medical School in New Brunswick, NJ. He earned dual majors in computer science, molecular biology/biochemisty, with a minor in cognitive science at Rutgers University, where he graduated summa cum laude. Dr. Su completed a two-year Society of Urologic Oncology fellowship at the National Cancer Institute, where his research and clinical efforts focused on the areas of fusion targeted prostate biopsy, focal treatment of prostate cancer, and salvage treatment of prostate cancer.

Dr. Su has experience in clinical research and conducting clinical trials. His research included advanced imaging for prostate malignancy, detection and screening for prostate cancer, treatment of multifocal kidney cancer, and neoadjuvant treatment of metastatic prostate cancer. Dr. Su is published in peer-reviewed journals including The Journal of Urology, European Urology, and British Journal of Urology.

“We are delighted that Dr. Su has decided to join Orange County Urology Associates,” OCUA President Dr. Paul Brower said. “He brings a stellar portfolio of clinical skills to our practice, and our patients will enjoy working with him.”

“I am very excited to be joining Orange County Urology Associates,” Dr. Su said. “I look forward to using my expertise in urology, and specifically urology oncology, to offer cutting edge treatment in order to improve the health of patients in Southern California.”

Dr. Su is bilingual and speaks Mandarin Chinese fluently. He enjoys outdoor activities such as hiking, snowboarding, and cycling. Dr. Su also is an amateur chef and pickle maker.

Watch Dr. Aaron Spitz on The Doctors TV show

imgres

In a show exclusive, Gretchen Rossi and fiancé Slade Smiley open up about their emotional journey to have a baby. The couple is best known for appearing on the reality show, The Real Housewives of Orange County.

After their IVF procedure did not yield a pregnancy, the couple turned to Dr. Aaron Spitz of Orange County Urology Associates to perform a vasectomy reversal on Slade. Dr. Spitz provides expert remarks on how a vasectomy reversal is performed.

To see all three videos from Jan. 11, 2016, exclusive story click here.

Dr. James Meaglia Performs First UroLift® Cases in Orange County

Sexual Dysfunction No Longer Inevitable When Treating Enlarged Prostate; Dr. James Meaglia Performs First UroLift^® Cases in Orange County

LAGUNA HILLS, Calif. (April 13, 2015)

Dr. James Meaglia of Orange County Urology Associates (OCUA) has performed the first surgical cases of UroLift® in Orange County. UroLift is a new treatment option for benign prostatic hyperplasia (BPH), which is also known as an enlarged prostate.

One in four men experience symptoms of an enlarged prostate by the age of 55, and that rate increases to 90 percent in men over the age of 70.

The new, minimally invasive UroLift is an outpatient surgical procedure approved by the FDA in the United States for the treatment of BPH that provides total preservation of sexual function.

“I have now done 15 surgical cases using the new UroLift surgical system for treating enlarged prostate, and couldn’t be more pleased with the patient and clinical outcomes,” Dr. Meaglia said. “I look forward to other urologic surgeons at Orange County Urology quickly adopting use of this new treatment system for surgical management of BPH.”

About BPH and the UroLift Treatment System

BPH is a common condition affecting more than 500 million aging men worldwide. Chronic lower urinary tract symptoms associated with BPH can cause loss of productivity and sleep, depression and decreased quality of life.

Medication is often the first line therapy, but relief can be inadequate and temporary. Side effects can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts or heats prostate tissue to open the blocked urethra. Although effective, patients have to “earn” their symptom relief after a difficult period of irritative voiding symptoms and catheterization.

Even the ‘gold standard’ surgery, TURP (transurethral resection of the prostate), can leave patients with permanent side effects such as urinary incontinence, erectile dysfunction (ED) and very commonly retrograde ejaculation (dry orgasm).

The UroLift system is designed to open the urethra directly without applying incisions, surgical resection or thermal injury to the prostate. Obstructive prostate lobes are transurethrally pushed aside and small permanent UroLift implants hold the lobes in the retracted position, thus opening the urethra while leaving the prostate gland intact. The prostate gland is similar in size and shape to a walnut.

Adverse reactions associated with the UroLift treatment system are comparable to other minimally invasive surgical therapies as well as standard cystoscopy. The most common adverse events reported during clinical trials included pain or burning with urination, blood in the urine, pelvic pain, urgent need to urinate, and the inability to control urine because of an urgent need to urinate. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure.

In a two-year randomized controlled study of UroLift in 206 people, which was published in Urology Practice (a journal of the American Urological Society), symptoms, quality of life, and urinary flow improved rapidly and remained durable to two years, with only 7.5% of the men who had the UroLift system needing additional BPH procedures. Treated men returned to normal activity within eight days and showed significant improvement in symptoms by two weeks. While urinary symptoms were effectively treated, not a single patient lost ejaculatory or erectile function as a result of the treatment.